Director of Clinical Pharmacology and Director of Translational Medicine at Innovent Biologics. Responsible for the design and evaluation of clinical pharmacology and translational medicine throughout the entire lifecycle of the company‘s product pipeline. Drugs such as Sintilimab, Tafolecimab have been approved and launched.
Also serves as the Early-stage Co-chair of the Product Development Committee and Project Leader for clinical product development.
Member of the Quantitative Pharmacology Committee of the Chinese Pharmacology Society, the Clinical Pharmacology Committee of the Chinese Pharmacology Society, and the Clinical Pharmacology Committee of the Shanghai Pharmacology Society.
信达生物临床药理部总监、转化医学部总监负责集团产品管线全生命周期临床药理、转化医学的设计和评价。其中，信迪利单抗、托莱西单抗等多款药物已获批上市。
信达生物产品开发委员会Early-stage Co-chair、产品开发Project leader。
中国药理学会定量药理学专业委员会委员、中国药理学会临床药理学专业委员会委员、上海药理学会临床药理学专业委员会委员。